Literature DB >> 32606201

Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy.

Tadaharu Nakasone1, Yusuke Taira2, Yuko Shimoji2, Yoshihisa Arakaki2, Tomoko Nakamoto2, Takuma Ooyama2, Wataru Kudaka2, Itomi Kaneshima2, Kumiko Nishihira2, Keiko Mekaru2, Yoichi Aoki2.   

Abstract

BACKGROUND/AIM: Radical hysterectomy has been used for local recurrent or persistent (LR) cervical cancer after radiotherapy (RT), but the rate of serious complications is high and tolerance is low. This study determined the efficacy, safety, and prognostic factors of adjuvant simple hysterectomy in LR cervical cancer post-RT. PATIENTS AND METHODS: A total of 21 patients who underwent hysterectomy for LR cervical cancer post-RT in our Department between May 2007 and September 2018 were included in the study. Primary, definitive RT was performed. Histological response by definitive RT in the extirpated uterus was classified on the basis of histological response criteria: effect (Ef) 0-3.
RESULTS: The 5-year overall survival (OS) and disease-free survival (DFS) rates were 51.9% and 50.1%, respectively. Ef 1 was significantly associated with poorer prognosis compared to Ef 2 or Ef 3.
CONCLUSION: Adjuvant hysterectomy could be a treatment of choice for LR cervical cancer post-RT. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cervical cancer; hysterectomy; radiotherapy

Mesh:

Year:  2020        PMID: 32606201      PMCID: PMC7439878          DOI: 10.21873/invivo.12026

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  14 in total

1.  Histological assessment of therapeutic response in breast cancer.

Authors:  Rie Horii; Futoshi Akiyama
Journal:  Breast Cancer       Date:  2013-10-31       Impact factor: 4.239

2.  Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy.

Authors:  A. Maneo; F. Landoni; G. Cormio; A. Colombo; C. Mangioni
Journal:  Int J Gynecol Cancer       Date:  1999-07       Impact factor: 3.437

3.  Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.

Authors:  Takafumi Toita; Ryo Kitagawa; Tetsutaro Hamano; Kenji Umayahara; Yasuyuki Hirashima; Yoichi Aoki; Masahiko Oguchi; Mikio Mikami; Ken Takizawa
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

4.  Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.

Authors:  Takafumi Toita; Shingo Kato; Satoshi Ishikura; Kayoko Tsujino; Takeshi Kodaira; Takashi Uno; Kazuo Hatano; Hideyuki Sakurai; Yuzuru Niibe; Tomoko Kazumoto; Tetsuo Nishimura; Ryo Kitagawa; Miki Fukutani; Masahiko Oguchi; Kenji Umayahara; Yasuyuki Hirashima; Yoichi Aoki; Ken Takizawa
Journal:  Int J Clin Oncol       Date:  2011-02-18       Impact factor: 3.402

5.  Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.

Authors:  Yutaka Nagai; Takafumi Toita; Akihiko Wakayama; Tomoko Nakamoto; Takuma Ooyama; Akemi Tokura; Morihiko Inamine; Wataru Kudaka; Sadayuki Murayama; Yoichi Aoki
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

Review 6.  Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.

Authors:  Sunati Sahoo; Susan C Lester
Journal:  Arch Pathol Lab Med       Date:  2009-04       Impact factor: 5.534

7.  Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.

Authors:  Kenji Umayahara; Munetaka Takekuma; Yasuyuki Hirashima; Shin-Ei Noda; Tatsuya Ohno; Etsuko Miyagi; Fumiki Hirahara; Eiji Hirata; Eiji Kondo; Tsutomu Tabata; Yutaka Nagai; Yoichi Aoki; Masaru Wakatsuki; Masahiro Takeuchi; Takafumi Toita; Nobuhiro Takeshima; Ken Takizawa
Journal:  Gynecol Oncol       Date:  2015-12-14       Impact factor: 5.482

8.  Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy.

Authors:  R L Coleman; E D Keeney; R S Freedman; T W Burke; P J Eifel; F N Rutledge
Journal:  Gynecol Oncol       Date:  1994-10       Impact factor: 5.482

9.  Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer.

Authors:  Yasuhiko Ebina; Mikio Mikami; Satoru Nagase; Tsutomu Tabata; Masanori Kaneuchi; Hironori Tashiro; Masaki Mandai; Takayuki Enomoto; Yoichi Kobayashi; Hidetaka Katabuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2018-10-05       Impact factor: 3.402

10.  Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.

Authors:  Peter G Rose; Shamshad Ali; Edwin Watkins; J Tate Thigpen; Gunter Deppe; Daniel L Clarke-Pearson; Samuel Insalaco
Journal:  J Clin Oncol       Date:  2007-05-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.